MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy

D Pelletier, S J Nelson, J Oh, J P Antel, M Kita, S S Zamvil, D E Goodkin

Primary progressive (PP) multiple sclerosis (MS) accounts for about 10% of patients with MS. They experience a progressive worsening from onset, and a lesser degree of inflammation found on histopathological reports compared to relapsing remitting (RR) and secondary progressive (SP) MS. Recent immunology studies in PP have found a positive correlation between brain T2 weighted lesion volume and BET. Recent immunology studies in PP have found a positive correlation between brain T2 weighted lesion volume and BET.

**Methods:** 34 PP MS patients were divided into two categories: low (<3 cm³, n = 18) or high (≥3 cm³, n = 16) T2 lesion load (T2LL). An Index of Brain Atrophy (IBA) was calculated and HMRS metabolite ratios were derived from a central brain area targeted at the corpus callosum.

**Results:** Patient groups did not differ with regard to clinical characteristics and showed lower mean IBA and mean N-acetylaspartate:creatinine (NAA:Cr) ratios compared to healthy controls.

**Conclusion:** PP patients with low and high T2LL have detectable brain atrophy and NAA:Cr reduction compared to healthy controls. In PP MS, T2 lesions alone are insufficient to explain the presence of brain atrophy and decrease in NAA:Cr.

**Brain atrophy measurement**

An index of brain atrophy (IBA) was measured using in-house software based on a similar technique previously reported. Supratentorial brain and CSF masks are created to remove skin, skull, and subcutaneous lipids. Both masks are used to calculate IBA as the ratio of (supratentorial brain parenchyma/supratentorial parenchyma + CSF) × 100. Reproducibility was determined by calculating the IBA of 10 healthy controls during two or three separate MRI sessions <15 days apart. Scan-rescan coefficients of variation (COV) (100% standard deviation/mean) were calculated between repeated measurements. Mean COV was 1.0%, representing about 99% reproducibility.

**HMRS imaging**

Brain HMRS imaging was obtained immediately following T1/T2 weighted images. Twenty eight subjects (18 PP patients, 10 healthy controls) were included. All PP patients met the following criteria: (1) abnormal cerebrospinal fluid (CSF) findings as defined by increased IgG index and/or presence of two or more oligoclonal bands not present in the serum; (2) a progressive course from onset for more than 12 months without acute exacerbation; and (3) no disease modifying or immunosuppressive therapies three months prior to the baseline scan. The Expanded Disability Status Score (EDSS) was performed the day of the MRI. Twenty five healthy age matched subjects were imaged. Informed consent was obtained for all subjects in accordance with the UCSF Ethics Committee.

**Abbreviations:** CB, central brain; COV, coefficient of variation; Cr, creatinine; CSG, cerebrospinal fluid; EDSS, Expanded Disability Status Score; HMRS, proton magnetic resonance spectroscopy; IBA, Index of Brain Atrophy; LL, lesion load; MRI, magnetic resonance imaging; MS, multiple sclerosis; NAA, N-acetylaspartate; NAWM, normal appearing white matter; PD, proton density; PP, primary progressive; ROI, region of interest; RR, relapse remitting; SP, secondary progressive
10 healthy controls) underwent a three dimensional echo planar spectroscopic imaging (3D-EPSI) sequence recently described, operating at TE = 144 ms, TR = 2000, FOV of 24 × 24 × 16 cm covering the entire supratentorial brain. From this large area a smaller central brain (CB) region of interest (ROI) measuring 9 × 9 × 2 cm (160 cm³) centred at the middle of the corpus callosum was delimited. Fifteen subjects (six PP patients, nine healthy controls) underwent a two dimensional chemical shifting imaging (2D-CSI) GE sequence operating at TR/TE = 1000/144 ms (same TE as 3D-EPSI), 24 × 24 × 1.5 cm and a press box positioned at CB, covering a slab of approximately 160 cm³ centred also at the middle of the corpus callosum. NAA:Cr ratios were estimated from voxels within the CB ROI using a linear regression analysis between height intensity of NAA over Cr.

Statistical analysis

Group comparisons were assessed using the Wilcoxon test to compare age, EDSS, disease duration, NAA:Cr, and IBA. Spearman’s correlation analysis was performed to compare T2LL, IBA, and NAA:Cr. In this study, a value of p < 0.05 is regarded as significant.

RESULTS

Table 1 presents clinical and MRI characteristics of all PP patients and controls. Female:male gender ratios for all PP patients (19/15) and controls (14/11) were similar: 1.267 and 1.272 respectively. Clinical characteristics for high and low LL PP groups. Although the high LL patients were found to be weak and statistically non-significant compared to low LL patient groups, the NAA:Cr metric did not reach statistical significance (p = 0.03). Finally, Spearman’s correlation coefficients for all PP patients were found to be weak and statistically non-significant (r = −0.36, p = 0.1) in the low LL group, the NAA:Cr metric did not reach statistical significance (p = 0.1) but the brain atrophy did (p = 0.03).

DISCUSSION

We have used a highly reproducible automated global brain atrophy measurement in conjunction with NAA:Cr metabolite ratios from CB to evaluate PP patients. Patients were divided into two separate groups based on their T2LL. Both patient groups had significant reduction of NAA:Cr and brain atrophy compared to controls. We also found no significant correlations between IBA and T2LL and between NAA:Cr and T2LL. The presence of brain MR visible T2 changes seems insufficient to explain the overall pathological process leading to brain atrophy and axonal injury. We speculate that PP MS may represent a more diffuse and global axonopathy. The formation and presence of focal MS lesions encompassing...
transected axons seem to have only an added effect to this axonal pathological process. This does not diminish the importance of such lesions, but their contribution to the development of more extensive brain tissue injury is perhaps marginal.

NAA:Cr ratio in CB has been proposed as an index of axonal damage and/or dysfunction for more than a decade as creatine concentration was found to be relatively constant in both lesions and NAWM of MS patients, although others have detected increased creatine. Several studies have found reduced NAA:Cr and concentration of NAA in MS lesions, NAWM, and whole brain of RR and SP patients, but only a few investigators evaluated PP specifically. In our study, the mean T2LL of all PP patients was 5.09 cm (ranging from 0.62 to 24.77 cm), representing <2% of the CB ROI volume used to derive NAA:Cr ratios (Table 1). Therefore, the decrease in NAA:Cr is not likely to be explained by changes in T2 weighted lesions. The extent of such reduction could reflect axonal injury in NAWM and perhaps in grey matter. Both patient groups showed marginal differences (Fig 1) compared to each other. The mean NAA:Cr ratio in the high LL group did not differ from the low LL group, although it was slightly lower. IBA seems to differ statistically between the two groups, favouring patients with lower T2LL. This does not necessarily suggest that CB NAA:Cr and IBA are unlinked measures in PP, although those metrics were found to be modestly correlated (r = 0.35, p = 0.1) in this study. Possible explanations for this discrepancy could be that the difference between the two groups is very subtle and requires a larger sample size, reduction of NAA might be an early event that could precede detectable tissue loss, and/or axonal injury being not the only element contributing to brain atrophy.

The relation between MR visible lesions and brain atrophy has also been challenged in numerous MS studies. Changes in brain volume and reduction of lesions in progressive MS patients treated with cladribine have been reported (70% SP and 30% PP patients). Although they observed a significant reduction in the number of gadolinium enhancing and volume of T2LL in the treated group, no effect was detected on brain atrophy. The authors concluded that MR lesions have a marginal role in the development of brain atrophy. Stevenson and colleagues found a significant change in brain atrophy between baseline and year 1 in a group of PP patients, but no correlations between brain atrophy and T2LL were reported.

We showed that axonal injury, as measured by HMRS imaging and brain atrophy are taking place in two groups of PP patients divided by their T2LL. Focal lesions seem to make a minimal contribution to global axonal injury, and other pathophysiological processes need to be explored in this particular form of MS. Based on this information, drug therapies in PP MS should not only target lesion formation but should also offer neuronal protection.

ACKNOWLEDGEMENTS

The National Institute of Health grant R01 NS39529-01A1 and the Immunix Corporation supported this study. Dr Pelletier is a National Multiple Sclerosis Society Physician Fellowship Award Grantee.

.................

Authors’ affiliations

D Pelletier, M Kito, S S Zavvili, D E Goodkin, Department of Neurology, University of California at San Francisco, CA, USA
S J Nelson, J Oh, Department of Radiology, University of California at San Francisco
J P Antel, Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

Competing interests: DE Goodkin was an employee of Immunix Corporation at the time of submission of this manuscript

Correspondence to: Dr D Pelletier, University of California at San Francisco, Multiple Sclerosis Center, 350 Parnassus Avenue, Suite 908, San Francisco, CA 94117, USA; danp@itsa.ucsf.edu

Received 15 May 2002
In revised form 12 November 2002
Accepted 13 December 2002

REFERENCES

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy
D Pelletier, S J Nelson, J Oh, J P Antel, M Kita, S S Zamvil and D E Goodkin

*J Neurol Neurosurg Psychiatry* 2003 74: 950-952
doi: 10.1136/jnnp.74.7.950

Updated information and services can be found at:
http://jnnp.bmj.com/content/74/7/950

These include:

**References**
This article cites 26 articles, 15 of which you can access for free at:
http://jnnp.bmj.com/content/74/7/950#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
- Immunology (including allergy) (1943)
- Multiple sclerosis (934)
- Radiology (1747)
- Radiology (diagnostics) (1309)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/